KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Net Margin (2016 - 2025)

Historic Net Margin for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q4 2025 value amounting to 10.17%.

  • Alnylam Pharmaceuticals' Net Margin rose 242900.0% to 10.17% in Q4 2025 from the same period last year, while for Dec 2025 it was 8.83%, marking a year-over-year increase of 212000.0%. This contributed to the annual value of 8.45% for FY2025, which is 208200.0% up from last year.
  • As of Q4 2025, Alnylam Pharmaceuticals' Net Margin stood at 10.17%, which was up 242900.0% from 20.1% recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Net Margin registered a high of 20.1% during Q3 2025, and its lowest value of 153.58% during Q3 2022.
  • For the 5-year period, Alnylam Pharmaceuticals' Net Margin averaged around 55.18%, with its median value being 57.68% (2023).
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Net Margin surged by 1732700bps in 2023, and later tumbled by -475000bps in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Net Margin stood at 99.97% in 2021, then soared by 38bps to 61.93% in 2022, then soared by 49bps to 31.35% in 2023, then surged by 55bps to 14.12% in 2024, then surged by 172bps to 10.17% in 2025.
  • Its Net Margin was 10.17% in Q4 2025, compared to 20.1% in Q3 2025 and 8.57% in Q2 2025.